Oncogenic PI3K mutations are as common asAKT1andSMOmutations in meningioma

Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy

(2015) Priscilla K. Brastianos et al.   JNCI-Journal of the National Cancer Institute

PI3K pathway inhibition in GBM—is there a signal?

(2015) Donna Nichol et al.   NEURO-ONCOLOGY

Phase II study of PX-866 in recurrent glioblastoma

(2015) M. W. Pitz et al.   NEURO-ONCOLOGY

Toward precision medicine in glioblastoma: the promise and the challenges

(2015) Michael D. Prados et al.   NEURO-ONCOLOGY

ARID1A and TERT promoter mutations in dedifferentiated meningioma

(2015) Malak S. Abedalthagafi et al.   Cancer Genetics

Genetic/molecular alterations of meningiomas and the signaling pathways targeted

(2015) Patrícia Domingues et al.   Oncotarget

Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy

(2015) Priscilla K. Brastianos et al.   JNCI-Journal of the National Cancer Institute

Angiomatous meningiomas have a distinct genetic profile with multiple chromosomal polysomies including polysomy of chromosome 5

(2015) Malak S. Abedalthagafi et al.   Oncotarget

Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy

(2014) C. Saura et al.   CLINICAL CANCER RESEARCH

GermlineSMARCE1mutations predispose to both spinal and cranial clear cell meningiomas

(2014) Miriam J Smith et al.   JOURNAL OF PATHOLOGY

Cross-reactivity of the BRAF VE1 antibody with epitopes in axonemal dyneins leads to staining of cilia

(2014) Robert T Jones et al.   MODERN PATHOLOGY

Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas

(2014) Priscilla K Brastianos et al.   NATURE GENETICS

Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review

(2014) T. Kaley et al.   NEURO-ONCOLOGY

Proposal for a new risk stratification classification for meningioma based on patient age, WHO tumor grade, size, localization, and karyotype

(2014) Patrícia Henriques Domingues et al.   NEURO-ONCOLOGY

Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma

(2014) Thomas J. Kaley et al.   NEURO-ONCOLOGY

Complex interactions between the components of the PI3K/AKT/mTOR pathway, and with components of MAPK, JAK/STAT and Notch-1 pathways, indicate their involvement in meningioma development

(2014) Elias A. El-Habr et al.   VIRCHOWS ARCHIV

Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations

(2013) David E. Reuss et al.   ACTA NEUROPATHOLOGICA

Loss-of-function mutations in SMARCE1 cause an inherited disorder of multiple spinal meningiomas

(2013) Miriam J Smith et al.   NATURE GENETICS

Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations

(2013) Priscilla K Brastianos et al.   NATURE GENETICS

Genomic Analysis of Non-NF2 Meningiomas Reveals Mutations in TRAF7, KLF4, AKT1, and SMO

(2013) V. E. Clark et al.   SCIENCE

PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies HarboringPIK3CAMutations

(2012) Filip Janku et al.   JOURNAL OF CLINICAL ONCOLOGY

DNA Fragmentation Simulation Method (FSM) and Fragment Size Matching Improve aCGH Performance of FFPE Tissues

(2012) Justin M. Craig et al.   PLoS One

Predictors of Visual Outcome Following Surgical Resection of Medial Sphenoid Wing Meningiomas

(2012) Christopher Jackson et al.   Journal of Neurological Surgery Part B-Skull Base

PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors

(2011) F. Janku et al.   MOLECULAR CANCER THERAPEUTICS

Epidemiology and etiology of meningioma

(2010) Joseph Wiemels et al.   JOURNAL OF NEURO-ONCOLOGY